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Alzheimer’s disease (AD) is the most common cause of dementia worldwide. One
of the main pathological changes that occurs in AD is the intracellular accumulation
of hyperphosphorylated Tau protein in neurons. Cyclin-dependent kinase 5 (CDK5) is
one of the major kinases involved in Tau phosphorylation, directly phosphorylating
various residues and simultaneously regulating various substrates such as kinases and
phosphatases that influence Tau phosphorylation in a synergistic and antagonistic way.
It remains unknown how the interaction between CDK5 and its substrates promotes
Tau phosphorylation, and systemic approaches are needed that allow an analysis of all
the proteins involved. In this review, the role of the CDK5 signaling pathway in Tau
hyperphosphorylation is described, an in silico model of the CDK5 signaling pathway is
presented. The relationship among these theoretical and computational models shows
that the regulation of Tau phosphorylation by PP2A and glycogen synthase kinase 3β
(GSK3β) is essential under basal conditions and also describes the leading role of CDK5
under excitotoxic conditions, where silencing of CDK5 can generate changes in these
enzymes to reverse a pathological condition that simulates AD.
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INTRODUCTION
Neurodegenerative diseases are a growing problem in the elderly
population. On such diseases is Alzheimer’s disease (AD), the
most common cause of dementia in people over the age of
65. Sporadic AD affects approximately 20 million people world-
wide, and in Colombia, there are approximately 1000 carriers of
the E280A mutation that causes early-onset AD (Lopera, 2002)
that have been described in the department of Antioquia. AD
is characterized by the abnormal folding and aggregation of the
β amyloid (Aβ) and Tau proteins, which favor the formation
of amyloid plaques and neurofibrillary tangles (NFTs), causing
brain atrophy with marked cognitive impairment as the disease
progresses (Jellinger, 2006; Querfurth and Laferla, 2010).
AD is characterized by two proteinopathies: amyloidopathy, a
product of the abnormal cleavage of the amyloid precursor pro-
tein (APP), which leads to the accumulation of Aβ peptide in
senile or amyloid plaques; and tauopathy, which is due to Tau
hyperphosphorylation and aggregation. Tau is associated with
microtubules (MTs) and, when it is abnormally phosphorylated,
dissociates and aggregates, resulting in the formation of paired
helical filaments (PHFs), which aggregate and form an insoluble
conformation called NFTs. These two proteinopathies generate a
loss of cell and tissue homeostasis during the neuropathological
process of AD, which leads to progressive neuronal degeneration
and the loss of the cognitive functions of the patient (Querfurth
and Laferla, 2010).
Several studies have shown that normal Aβ processing is per-
formed by a protease called α-secretase that cleaves APP to release
a soluble extracellular fragment of 695 amino acids. The frag-
ment that remains integrated in the membrane is processed
by the action of a second enzyme, γ-secretase, releasing the
carboxy-terminal part of the protein. This is known as the non-
amyloidogenic pathway because the action of α-secretase prevents
the formation of the Aβ peptide, preventing deposit formation
(Jellinger, 2006; Querfurth and Laferla, 2010).
However, in the amyloidogenic pathway, one fragment of
APP is processed differently. Another secretase, called β-secretase,
cleaves APP, releasing a longer carboxy-terminal fragment, which
releases the Aβ peptide after being processed by γ-secretase (Li
and Sudhof, 2004). This peptide has limited solubility and forms
auto-aggregates, which constitute the insoluble fibrils that are
found in senile plaques. The actions of β-secretase and γ-secretase
produce several types of Aβ peptides; the most common form is
relatively soluble and has 40 amino acids (Aβ 40), whereas other
forms that are less soluble have a length of 42 or 43 residues (Aβ
42–43) (Li and Sudhof, 2004).
The formation of NFTs due to the aggregation of amyloid
plaques has been described in AD (Ingelsson, 2004). These struc-
tures are due to an abnormal increase in the phosphorylation of
Tau associated with MTs and neurofilaments (NFs), preventing
their assembly and stabilization, which is important for axonal
growth and internal axonal transport (Avila et al., 2004). Tau is
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phosphorylated by different kinases that regulate its function and
its binding to the neuronal cytoskeleton. Increased phosphory-
lation, known as hyperphosphorylation, may lead to a loss of
function; avoiding the binding or detaching of Tau from MTs
and causing its accumulation in the cytoplasm. This leads to the
formation of PHFs, the extracellular accumulation of NFTs and
subsequent brain damage (Grundke-Iqbal et al., 1986; Ingelsson,
2004).
In recent years, the central role of Aβ in AD has been ques-
tioned. It has been postulated that the production of Aβ peptide in
quantities larger than normal is related to the origin of the disease
and produces NFTs as a result of the damage inflicted by the pres-
ence of Aβ (Ferrari et al., 2003; Gotz et al., 2004). Another idea,
based on the existence of dementia without senile plaques and
dementia associated with parkinsonism linked to chromosome
17, or frontotemporal dementia, suggests that Tau hyperphos-
phorylation and the subsequent deposition of the protein is the
main cause of neurodegeneration (Iqbal et al., 2005; Iqbal and
Grundke-Iqbal, 2005). Although both postulates are part of the
possible explanations for the phenomenon of neurodegeneration,
only continued study of the particular context of AD will identify
means of action and therapeutic possibilities.
Currently, much is known about the proteins associated with
the development of tauopathy, but very little is known about the
interaction between the set of proteins involved in Tau hyper-
phosphorylation and the subsequent development of tauopathy.
Although the central importance of the kinases cyclin-dependent
kinase 5 (CDK5) and glycogen synthase kinase 3β (GSK3β) and
the protein phosphatases 1 (PP1) and 2A (PP2A) in this pro-
cess has been described, it is not known with certainty how they
interact and how this interaction contributes to Tau hyperphos-
phorylation in different states of kinase activation. This review
aims to describe and model in an integrated manner the CDK5
kinase pathway as related to Tau hyperphosphorylation. This
strategy outlines and groups isolated experimental data of the
molecular species, or proteins, involved in CDK5 and Tau phos-
phorylation, describing the behavior of the signaling pathway in
a pathological process such as AD.
SYSTEMS BIOLOGY
Systems biology (SB) is a scientific research approach that brings
together knowledge from various disciplines to the study of living
organisms from a systems perspective that assumes the compo-
nent parts as a whole and the interactions between the compo-
nents as their functional dynamics. Thus, cellular organization
is described at different functional levels, ranging from the more
specific intracellular processes (signaling pathways) to intercellu-
lar processes (neural networks). SB addresses the living organisms
as an integrated and interacting network of genes, proteins, lipids,
carbohydrates, and biochemical reactions from which life arises
and persists (Yang et al., 2014).
The systems approach is not new, and many have worked
to develop this idea. One of the most important developers
was Bertalanffy, with his General Systems Theory published in
1969. In this paper, a system was defined as a set of objects
united by some form of interaction or interdependence, displac-
ing the idea that a system is only the sum of its components
(Bertalanffy, 1969). The result was the study of living organisms as
complex systems composed of elements that interact in complex
ways and that emergent properties arise out of these interactions,
which finally define the behavior of a system in a specific time and
place (Yang et al., 2014).
Recently, SB has gained great interest in the scientific commu-
nity due to the huge amount of data arising from the application
of new high-throughput technologies and the inability of scien-
tists to integrate and interpret this vast amount of information.
From this point comes the need for approaches to integrate infor-
mation and study the interaction between the molecular species
identified; it is then when mathematical models arise as a possi-
bility to simulate biological systems, integrating the data obtained
experimentally and taking into account the interactions between
the system components (Bowers and Boloure, 2001; Klipp et al.,
2005).
The implementation of SB requires a process that can be
defined in three basic steps. The first step involves the enumer-
ation of the biological components involved in the process of
interest, i.e., proteins, genes, lipids and other molecular species
that are part of the system. The second step is to study the interac-
tions of these components and generate a diagram that identifies
system elements and their relationships; in this step, signaling
pathways or routes of biochemical reactions are built. In the third
step, these signaling pathways are reconstructed mathematically,
creating computer models that emulate the behavior of the sys-
tem, for analyzing, interpreting and predicting the functions of
the phenomenon of interest (Palsson, 2006).
FIRST STEP: BIOLOGICAL COMPONENTS
TAU PROTEIN
The Tau protein was discovered in 1975 when it was found to
be involved in the in vitro assembly of MTs added to tubulin
(Murphy and Borisy, 1975; Weingarten et al., 1975). In humans,
Tau is located on chromosome 17 and occupies approximately
100 kb with 16 exons. Tau localizes mainly to the brain, and
6 isoforms have been identified in the central nervous system,
each of which contains two domains: the amino-terminal projec-
tion domain and the carboxy-terminal MT-binding domain. The
projection domain is further divided into an acidic residue-rich
region and a proline-rich region, and the MT-binding domain
is divided into the basic region, tubulin-binding region and the
acidic region (Avila et al., 2004; Hernandez et al., 2008).
Tau protein is easily phosphorylated, allowing the mobility of
the protein within the neuron. When Tau is phosphorylated at
proline-rich regions, it is distributed in somatodendritic com-
partments; when this region is dephosphorylated or when Tau
is phosphorylated at its carboxy-terminal region, Tau is located
in the distal part of axons (Mandell and Banker, 1996; Tashiro
et al., 1997; Avila et al., 2004). Tau phosphorylation sites are
divided into two types: those that can be modified by ser-
ine/threonine proline-directed kinases such as CDK5, GSK-3,
mitogen-activated protein kinase (MAPK) and c-Jun N-terminal
kinase (JNK), and non-proline-directed kinases such as MT
affinity-regulating kinase (MARK), protein kinase A (PKA), pro-
tein kinase C (PKC), and Ca2+/calmodulin-dependent protein
kinase II (CaMKII) (Trinczek et al., 1995; Reynolds et al., 2000;
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Avila et al., 2004; Wang et al., 2007; Yu et al., 2009). Depending on
the phosphorylation pattern established by the kinases, different
Tau functions are regulated in the cellular space.
The role of the Tau protein in the cell is directed by the estab-
lishment of MT dynamics and the stability of MTs in the cell
(Witman et al., 1976; Trinczek et al., 1995; Tashiro et al., 1997).
The function of Tau has been linked to the formation of cyto-
plasmic extensions, axonal transport and protection against dele-
terious compounds due to its association with MTs (Kosik and
Finch, 1987; Lesort et al., 1997; Dawson et al., 2001; Johnson and
Stoothoff, 2004). In Tau-deficient mice, a reduction in the num-
ber of MTs, small caliber axons, muscle spasms and behavioral
deficits have been identified, although MT-associated protein 2
(MAP2) has been observed to partially compensate for the low
Tau level (Dawson et al., 2001).
In AD and other tauopathies such as progressive supranuclear
palsy (PSP) and frontotemporal dementia associated with parkin-
sonism linked to chromosome 17, a phenomenon of abnormal
Tau hyperphosphorylation or phosphorylation is responsible for
a set of alterations, such as axonal transport and mitochondrial
and lysosomal dysfunction, among other functions associated
with MTs, that can lead to neuronal degeneration (Avila et al.,
2004; Iqbal et al., 2009). Upon the abnormal action of kinases and
phosphatases, Tau dissociates from MTs and accumulates in the
cytosol in packages of the abnormal PHFs, which in turn aggre-
gate to form NFTs (Grundke-Iqbal et al., 1986; Anderton et al.,
1995; Mandelkow et al., 2007) (Figure 1). The conditions that
facilitate the aggregation and the formation of these structures are
still unknown, but studies on the cellular context involved in this
phenomenon are vitally important.
CDK5
The family of cyclin-dependent kinases is a group of proteins
involved in the regulation of DNA replication and cell division
that control the transition from G1 to S phase and from G2 toM
phase in the cell cycle. In humans, 10 members of the family have
been described. Their function is regulated when a cyclin binds
and activates a kinase, stimulating phosphorylation of its targets
on serine/threonine-proline sequences. One member of this fam-
ily is CDK5, which has 60% homology with CDK2 and has little
involvement in the regulation of the cell cycle. CDK5 is highly
conserved among species, and its expression is predominant in
the nervous system. The function of CDK5 is not regulated by
cyclins (Dhavan and Tsai, 2001; Ip and Tsai, 2008).
In the nervous system, CDK5 involvement has been described
in neurite outgrowth, axonal guidance, neuronal migration,
secretion, cytoskeletal dynamics, dopaminergic signaling, neu-
ronal differentiation, synaptic transmission, neuronal survival,
apoptosis and other functions that are still under study (Ip and
Tsai, 2008). CDK5 also plays a role inmolecular macro-complexes
involved in intracellular transport, various signaling pathways
and a large number of identified substrates that are related to the
previously mentioned functions (Ip and Tsai, 2008). The major-
ity of CDK5-deficient mice die in utero, and embryos that are
born do not live more than 10 days postpartum. Post-mortem
analyses show marked alteration in the formation of cortical,
FIGURE 1 | Scheme of CDK5 signaling pathway involved in Tau phosphorylation. This draw shows the CDK5 signaling pathway describing direct and
indirect Tau phosphorylation by CDK5.
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hippocampal and cerebellar layers, suggesting that CDK5 is essen-
tial for neuronal development (Ohshima et al., 1996; Fu et al.,
2005).
CDK5 expression has been observed in different organs
(Rosales and Lee, 2006), but the highest level of expression is
found during brain development and in the adult nervous system.
Its p35 and p39 activators have been found to be especially highly
expressed in the brain, and although they are not cyclins and have
very low homology with cyclins, their folded structure is quite
similar to cyclin molecules involved in the cell cycle (Zheng et al.,
1998; Ko et al., 2001; Kesavapany et al., 2003; Ip and Tsai, 2008).
p35 and p39 have 57% homology with each other but exhibit dif-
ferent temporal and spatial expression patterns in developing and
adult neurons (Zheng et al., 1998; Ko et al., 2001). Although indi-
vidual deletion of p35 and p39 in mice does not duplicate the
phenotype of CDK5-deficient animals, mice deficient for both
activators do phenocopy CDK5 knockout; it is possible that the
presence of one activator can compensate for the absence of the
other (Ko et al., 2001).
Neuronal differentiation, which is characterized by dendritic
growth, axon formation and the establishment of synapses,
involves a wide variety of CDK5 substrates; these proteins modu-
late the cytoskeleton through actions on actin filaments, NFs and
MTs to promote the development of the growth cone and neurite
extension/retraction (Cheung and Ip, 2007). CDK5 inhibition in
primary cortical cultures prevents neurite outgrowth; the involve-
ment of p35 and p39 in growth cones and CDK5 association with
members of the Rho/Rac GTPase (Ras-Homologous/Ras-related
C3 Botulinum Toxin Substrate Guanosine Triphosphatase) fam-
ily have also been reported (Nikolic et al., 1996; Ko et al., 2001;
Angelo et al., 2006; Kawauchi et al., 2006). Of these family
members, Rac binds to CDK5/p35 in a molecular complex that
phosphorylates its effector PAK (p21-activated kinase), which
regulates actin polymerization/depolymerization (Rashid et al.,
2001).
The association of CDK5 with NFs and MTs has also been
described; NFs are intermediate filaments associated with the
dynamics of actin, MTs and axon formation. Moreover, MTs
are tubulin polymers that, like NFs, maintain cell shape but are
also associated with intracellular transport by the motor pro-
teins dynein and kinesin. CDK5 regulates NF function, as well as
MTs. CDK5 phosphorylates NFs directly and also phosphorylates
MT-associated proteins such as MAP2, MAP1b, and Tau, which
induces the formation and stability of MTs when phosphorylated.
CDK5 also regulates the NUDEL protein, which is associated with
dynein motor activity (Ohshima et al., 1996; Niethammer et al.,
2000; Cicero and Herrup, 2005; Zheng et al., 2007).
The balance of CDK5 activation and its phosphorylation of
different substrates is key for the proper performance of the neu-
ral network, synapses and for neuronal plasticity; changes that
may affect this balance have been associated with pathological
conditions such as AD, amyotrophic lateral sclerosis, Parkinson’s
disease and cerebral ischemia, among other disorders (Ip and
Tsai, 2008). Imbalances in CDK5 are associated with alterations of
the cytoskeleton, induction of apoptosis, increases in N-methyl-
D-aspartic acid (NMDA) receptor-dependent calcium influx and
other cell imbalances that can lead to hyperphosphorylation of
different CDK5 substrates (O’hare et al., 2005; Plattner et al.,
2006; Wen et al., 2007; Ip and Tsai, 2008; Querfurth and Laferla,
2010).
In AD, the relationship of CDK5 with Tau has been described;
the CDK5/p35 or CDK5/p39 complex regulates the normal
function of Tau in the cytoskeleton. Upon activation, CDK5
phosphorylates its p35 activator, and possibly p39, to induce
proteasome-dependent degradation by regulating the duration
of kinase activation (Hamdane et al., 2003; Iqbal et al., 2009;
Peterson et al., 2010). In a pathological process such as AD, the
activation of the calcium-dependent proteases m-calpain or μ-
calpain can produce cleavage of the p35 and p39 activators, gen-
erating the p25 and p29 proteins, which are CDK5 activators with
increased stability that induce a prolonged activation of CDK5
(Kerokoski et al., 2004; Peterson et al., 2010). This overactiva-
tion leads to hyperphosphorylation of different substrates, in this
case the Tau protein, leading to PHF formation, the subsequent
formation of NFTs and the disruption of the cytoskeleton and
intracellular transport, inducing neurodegeneration (Ahlijanian
et al., 2000; Hamdane et al., 2003) (Figure 3).
Despite the evidence linking CDK5 with Tau hyperphospho-
rylation, a consensus has not yet been reached on the role of
CDK5 in the development of AD. However, there are some Tau
phosphorylation sites for which CDK5 is known to be impor-
tant, such as Thr181, Ser199, Ser202, Thr205, Thr212, Ser214,
Thr217, Thr231, Ser235, Ser396, and Ser404, which are involved
in the formation of PHFs (Gong et al., 2005; Wang et al., 2007). In
addition, increased CDK5 immunoreactivity has been observed
in neurons that begin the formation of NFTs compared with
neurons that are part of mature NFTs (Gotz and Nitsch, 2001).
Studies using compounds that promote the release of p25 and p29
by increased calcium influx, such as glutamate, NMDA, Aβ, and
calcium ionophores, and those that describe the overexpression
of p35, p25, and CDK5 show strong evidence for the involve-
ment of CDK5 in Tau hyperphosphorylation and NFT formation
(Ahlijanian et al., 2000; Kerokoski et al., 2002; Zheng et al., 2002,
2005; Hamdane et al., 2003; Plattner et al., 2006; Sengupta et al.,
2006; Wang et al., 2007; Peterson et al., 2010). These studies sug-
gest the involvement of CDK5 in AD, dependent on the cellular
context, but without a doubt, CDK5 is one of the factors involved
in its progression.
SYSTEMS BIOLOGY AND TAUOPATHY
SB approaches are currently being used to improve the under-
standing of AD. The main objectives of these studies are to model
the interaction of genes and protein expression patterns and val-
idate signaling pathways that are involved in the development
of this disease. To this end, high-throughput techniques such as
microarrays, which help to identify gene expression patterns in
different stages of the disease, are used; proteomics approaches
that provide knowledge of proteins that play a role in patholog-
ical processes and biomarkers of AD progression are also used.
Mathematical models can integrate this information and are used
to analyze signaling pathways where new therapeutic targets are
being evaluated (Pasinetti and Hiller, 2008; V, 2009).
Tau has also been studied from the standpoint of SB; one
study simulated the importance of Tau phosphorylation for MT
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assembly. This research concluded that different isoforms of Tau
may have different conformations depending on the degree of
phosphorylation and that these conformations influence the abil-
ity of Tau to bind to MTs. Furthermore, this study suggests that
the phosphorylation pattern neutralizes the net positive charge
of Tau residues, disfavoring their interaction with the negative
charges of MTs that cause MT uncoupling and favoring the
aggregation of Tau (Jho et al., 2010).
Some SB approaches have included CDK5 in mathematical
modeling and have highlighted its importance in the function and
regulation of other proteins. One model evaluated the regulation
of phosphorylation sites of the dopamine- and cAMP-regulated
neuronal phosphoprotein (DARPP-32) (Fernandez et al., 2006;
Lindskog et al., 2006; Nakano et al., 2010; Qi et al., 2010).
Other researchers have modified and supplemented this model by
including new elements and conducting various in silico experi-
ments (simulations), making this an ever closer approximation of
the phenomenon that helps in better understanding the regula-
tion of DARPP-32.
The DARPP-32 modeling included combinations of phospho-
rylation sites, its regulation by kinases and phosphatases and
the influence of calcium and cAMP on these enzymes. The in
silico experiments simulated changes in the levels of calcium
and cAMP and the level and activity of each of the participat-
ing elements. The results from the different simulations were
useful for understanding the influence of calcium and cAMP
signals and the importance of each of the proteins included in
the model. The variations in CDK5 activity and level showed
that this kinase is a key player in the regulation of DARPP-32
and that the phosphorylation of DARPP-32 substantially affects
its activation by inhibiting the action of PKA (Fernandez et al.,
2006; Lindskog et al., 2006; Nakano et al., 2010; Qi et al.,
2010).
The degree of Tau phosphorylation, the importance of phos-
phorylation in the aggregation of the protein and the influence
of different enzymes on this process have been studied separately
but without simultaneously taking into account the interactions
among three phenomena. Thus far, this phosphorylation pro-
cess and the influence of kinases such as CDK5 have not been
described using an in silico model; this type of approach may aid
in understanding the direct influence of CDK5 on Tau aggrega-
tion and the involvement of CDK5 in the regulation of substrates
that mediate Tau phosphorylation.
STEP TWO: COMPONENT INTERACTION
To select and describe the components and interactions that are
part of the CDK5 signaling pathway, it was necessary to per-
form a specialized information search using PubMed as a tool to
access MEDLINE, the largest database of scientific literature that
currently exists for biomedical sciences. Medical subject heading
(MeSH) search terms, which allow a keyword search that is orga-
nized by subject headings, qualifiers (subheadings), definitions,
synonyms and lists of closely related terms, were used to con-
duct this search. Of the retrieved documents, only original articles
where the experimental design showed a direct biochemical con-
nection with CDK5 and the substrate and that fit the description
of a signaling pathway associated with Tau phosphorylation were
selected. A description of the selected information is presented
next.
ROLE OF CDK5 IN TAU HYPERPHOSPHORYLATION
Brain disorders caused by chronic conditions such as AD or acute
disorders such as cerebral ischemia, among other pathologies,
promote excitotoxicity or an alteration of cellular homeostasis
that triggers an increase in glutamate concentration; glutamate
binds and activates glutamate-dependent calcium receptors such
as NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) and kainate receptors. When activated, these chan-
nels allow an influx of calcium and, in turn, promote the
activation of calcium-dependent signaling pathways (Kerokoski
et al., 2004). Excessive activation of these receptors may trig-
ger the onset of pathological processes and even activate path-
ways involved in neuronal cell death (Lau and Tymianski, 2010).
NMDA receptors are the most important of these receptors as
theymaintain activity for a longer period of time and allow higher
calcium influx (Goll et al., 2003).
The influx of calcium into the cell activates calpain, a calcium-
dependent thiol protease that cleaves the CDK5 activator p35
to p25 and p10 (Patrick et al., 1999). The p35/CDK5 complex
phosphorylates p35 and becomes an auto-regulation signal that
induces ubiquitination and the subsequent degradation of p35
through the proteasome (Patrick et al., 1998). Calpain cleavage
eliminates this regulatory site so that p25 forms a more sta-
ble complex with CDK5, increasing its activity, which may lead
to a long-term increase in Tau phosphorylation and neurode-
generation (Cruz et al., 2003). Moreover, the cleavage of p35
eliminates a myristoylation motif that anchors p35 to the mem-
brane; this causes the p25/CDK5 complex to lose the peripheral
membrane distribution of p35/CDK5 and allows the complex
to access other types of substrates, suggesting that this process
may be important for neurodegeneration (Ahlijanian et al., 2000)
(Figure 1).
Phosphorylation of other substrates by CDK5 may indirectly
promote Tau hyperphosphorylation. CDK5 has been described
to play an important role in the activity of GSK3β, a ser-
ine/threonine kinase that is directly associated with Tau hyper-
phosphorylation (Mandelkow et al., 1992). Certain types of Tau
phosphorylation by CDK5 increase GSK3β kinase activity for Tau;
that is, the phosphorylation of Ser235 and 404 by CDK5 promotes
an increase in GSK3β-mediated phosphorylation of Thr231 and
Ser400 and 396, indicating that higher activity of CDK5 can gen-
erate increased Tau phosphorylation by GSK3β (Li et al., 2006)
(Figure 1).
CDK5 can phosphorylate and promote the activation of epi-
dermal growth factor (ErbB) receptors; when activated by the
binding of neuregulin, a member of the family of epidermal
growth factor proteins, ErbB receptors induce the phosphory-
lation and activation of protein kinase B (PKB) and AKT, a
serine/threonine kinase that is involved in cell survival pathways
(Li et al., 2003) and that inactivates GSK3β by phosphorylation
at Ser9 (Cross et al., 1995; Wen et al., 2008). This indicates that
CDK5 regulates GSK3β activity through different mechanisms
and that CDK5 deregulation can promote the phosphorylation
of Tau by GSK3β (Figure 1).
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Phosphatases are another class of proteins involved in Tau
activity; these proteins regulate the degree of Tau phosphoryla-
tion by dephosphorylating various residues. The most important
phosphatases for Tau dephosphorylation are PP1 and PP2A,
which show high activity for Tau (Liu et al., 2005). These phos-
phatases in turn regulate other substrates involved in the signaling
pathway. Initially, PP1 activates GSK3β through dephosphoryla-
tion of Ser9 (Bennecib et al., 2000; Hernandez et al., 2010), and
PP2A dephosphorylates and regulates AKT, inhibiting its activity
on GSK3β (Mora et al., 2002; Resjo et al., 2002). Thus, phos-
phatases influence Tau phosphorylation through several mech-
anisms, and in a pathological condition such as AD where
phosphatase activity is decreased (Liu et al., 2005), these enzymes
are key factors in the development of the disease (Figure 1).
CDK5 is involved in the regulation of PP1 through phospho-
rylation of inhibitor-1 (I1) and inhibitor-2 (I2), two regulators
that bind to PP1 and inhibit its activity (Oliver and Shenolikar,
1998). The dephosphorylated form of I2 binds to and inhibits
PP1; CDK5 and GSK3β phosphorylate PP1 at Thr72, prevent-
ing I2 from acting upon PP1 (Agarwal-Mawal and Paudel, 2001).
Unlike I2, the dephosphorylated form of I1 remains inactive and
does not exert any function on PP1, whereas I1 phosphorylated at
Thr35 and/or Ser67 by PKA and CDK5 binds to and inhibits PP1
(Huang and Paudel, 2000). In addition, CDK5 phosphorylates I1
at Ser6, which has no direct effect on the activity of I1; however, it
has been described that I1 phosphorylated at Ser6 is less suscep-
tible to dephosphorylation at Thr35 and thus remains active for a
longer period of time (Nguyen et al., 2007) (Figure 1).
It is important to note that CDK5 is a kinase that plays a key
role in regulating Tau phosphorylation either directly or by the
regulation of other substrates. This signaling pathway describes
a set of proteins and the relationships among them that support
the influence of CDK5 on phosphorylated Tau; however, CDK5
and the described proteins have an interdependent network of
relationships that we cannot cover in full using this theoretical
and mathematical approach. To evaluate the participation of each
of the proteins described in the signaling pathway, we confirmed
the in silico analysis of the model by supporting our data and the
relationship among the proteins in the signaling pathway.
STEP THREE: MATHEMATICAL MODELING
Mathematical modeling was performed to define the parts of the
system and the way they interact with each other by means of
mathematical equations. The model was described based on two
types of reactions: binding, which can be described as the pro-
cess of association and dissociation of two ormoremolecules, and
enzymatic, where an enzyme binds to a substrate and converts it
into a product. For the analysis of all components, ordinary differ-
ential equations were used that allow the description of the change
in concentration of the different molecular species over time.
Once the molecular species and the reactions involved in
the system (Table 1) were defined, the mathematical description
of each of the reactions was performed separately according to
the previously mentioned equations. Next, the coupling of the
equations with common reactants was performed, which sim-
plified the model because it consists of a large set of reactions
occurring simultaneously. It is worth noting that the coupling
of equations allows for any change in the concentration of the
molecular species to interfere with the variations of other species.
By way of example, the following reactions are illustrated:
A+B → A.B
A+C →A.C → C+B
If each reaction occurs separately, the reactions will invariably end
up forming B and A.B, and none of the species will influence the
other. However, if these reactions occur simultaneously and in
the same place, the result will be different because the change
in the concentration of A depends on its binding to B and C;
in reactions 1 and 2, the concentrations of C and B depend on
other reactions that occur in 1 or 2. This example illustrates the
interdependence that different molecular species may have, and
therefore, it is necessary for these relationships to be reflected in
the coupled differential equations.
After coupling the equations describing the reactions, a set
of 40 ordinary coupled differential equations was built that was
dependent on 62 reaction parameters or constants and 40 initial
concentrations. The model was run at an initial concentration
of 0.1μM baseline calcium, and then a series of simulations
were performed that consisted of variations in the concentration
and reaction speed of the different molecular species. Initially,
variations were made in calcium levels, the enzymatic activity
of phosphatases and kinases was changed, the effect of various
knockouts in silico (KOis) was tested, and in silico silencing (SIS)
of CDK5 and GSK3β was evaluated under different conditions.
The model and the simulations that were performed used
calcium influx as input and the levels of unphosphorylated or
phosphorylated Tau (pTau) as output, noting the ratio between
the two. Specific Tau phosphorylation events were not taken into
account because of difficulties with assigning constants that could
account for a different phosphorylation pattern from normal;
therefore, pTau is assumed to be an indicator of the level of phos-
phorylation, and increased pTau is regarded as a trend indicating
hyperphosphorylation.
Tau and pTau levels were studied at basal conditions; i.e., the
model was run without any modification. It was found that Tau
and pTau levels were balanced, indicating that approximately 50%
of total Tau and pTau were constant (Figure 2). This suggested
that there was a balance between the action of kinases and phos-
phatases, which is consistent with the known regulation of both
types of enzymes, because Tau phosphorylation state depends on
both the relationship between phosphatases and kinases and the
role of these proteins in various pathological states such as AD
(Wang et al., 2007; Morris et al., 2011).
To examine the sensitivity of the model to variations in dif-
ferent molecular species, KOis were performed that consisted of
completely suppressing the activity of the molecular species by
reducing the K2 constant (Vmax) to a number very close to zero.
It was observed that the model was sensitive to dramatic changes
in GSK3β, which decreased pTau levels to 40.5%, and changes in
PP2A, which increased pTau levels to 56%. The KOis of CDK5
showed a change in pTau of 13%, and the KOis of PP1 did not
alter pTau significantly (Figure 3). These results show that the sys-
tem is more sensitive to proteins that have little regulation in our
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Table 1 | Reactions and velocity constants.
Reations K1 (μM−1S−1) K_1(S−1) K2(s−1) Source
cal+ca↔cal.ca 1 20 Bhalla and Iyengar, 1999
cal.ca+p35↔cal.ca.p35→cal.ca+p25 0.12 0.44 0.11 Brenda
P35+CDk5↔p35.CDK5 20 1 Estimated
P25+CDk5↔p25.CDK5 20 0.1 Estimated
p35.CDk5+Tau↔p35.CDk5.Tau→p35.CDk5+pTau 0.007 0.17 0.043 Kerokoski et al., 2004
p25.CDK5+Tau↔p25.CDk5.Tau→p25.CDk5+pTau 0.04 0.88 0.22 Kerokoski et al., 2004
GSk3b+Tau↔GSk3b.Tau→GSK3b+pTau 0.012 0.24 0.06 Estimated
PP1+pTau↔pTau.PP1→Tau+PP1 0.01 0.08 0.02 Lau and Tymianski, 2010
pp2a+pTau↔pTau.PP2a→Tau+PP2a 0.017 0.16 0.04 Lau and Tymianski, 2010
GSk3b+pAKT↔GSk3b.pAKT→pGSk3b+pAKT 0.2 0.76 0.19 Brenda
PP1+pI1↔PP1.pI1 499.98 0.1 DOQCS
PP1+12↔PP1.12 200 1 Estimated
P35.CDK5+11↔P35.CDK5.11→P35.CDK5+pI1 0.3 7.6 1.9 Brenda
P25.CDK5+11↔P25.CDK5.11→P25.CDK5+pI1 0.6 8.9 2.3 Estimated
P35.CDK5+12↔P35.CDK5.12→P35.CDK5+pI2 0.05 0.8 0.2 Brenda
P25.CDK5+12↔P25.CDK5.12→P25.CDK5+pI2 0.082 1.12 0.28 Estimated
GSk3b+11↔GSK3b.11→GSK3b+pI1 0.047 0.72 0.18 Estimated
pl1 +PP2a↔p11.PP2a→PP2a+11 3.832 24 6 DOQCS
pGSK3b+PP1↔pGSK3b.PP1→GSK3b+PP1 25.56 55.2 13.8 Estimated
PP2A+pAKT↔PP2A.pAKt→PP2A+AKT 1.875 7.2 1.8 DOQCS
p25.cdk5+AKT↔p25.cdk5.Akt→p25.cdk5+pAkt 2.83 6.8 1.7 Estimated
p35.cdK5+Akt↔p35.cdk5.Akt→p35.cdk5+pAKt 1.15 4.1 1.0 Estimated
p35→ Ø 0.01 Ø Estimated
Descriptions of Reactions and velocity constants that form the model of the CDK5 signaling pathway involved in Tau phosphorylation.
FIGURE 2 | Change in Tau and pTau levels at basal conditions. There are
stable behavior between two forms of Tau
model; despite this, the model is stable to 100% variation because
the maximum change generated only represented a 56% increase
in pTau specifically with the KOis of PP2A.
After evaluating Tau and pTau levels at basal conditions, cal-
cium levels were increased by 2-, 10-, and 100-fold from an
initial concentration of 0.1μM. Thus, an unbalanced condition
of calcium homeostasis or an excitotoxic process, which is charac-
teristic of pathological processes, was simulated. With increasing
calcium concentration, pTau increased, reaching even a 28%
increase over the initial condition (Figure 4). This indicates that
calcium levels are a key factor in Tau phosphorylation; a sig-
nificant increase in calcium influences the activity of CDK5 by
activating calpains and promoting p25/CDK5 complex forma-
tion, which then has the ability to phosphorylate Tau over a longer
period of time.
The simulation of a 100-fold increase calcium added to SIS
of GSK3β allowed the observation of the influence of this pro-
tein in a condition of excitotoxicity. A 75% decrease in the levels
of GSK3β reduced pTau by 11%; although this is a significant
reduction, we note that it is less than the 15% achieved by
CDK5 reduction under the same conditions (Figure 5), unlike
what was observed in the KOis under basal conditions (Figure 3).
This result shows the importance of CDK5 and GSK3β and the
importance of both in Tau phosphorylation under conditions of
increased calcium levels.
In AD, it has been described that the excitotoxic process, as
well as the increase in p25-mediated CDK5 activity and a decrease
in the activity of phosphatases, plays a key role in the devel-
opment of the disease. To simulate a similar condition, calcium
concentration was increased by 100-fold, and the activity of both
phosphatases was decreased by 50% (Figure 6). Under these con-
ditions, the simulation of the pathological condition significantly
increased pTau concentration (46%) (Figure 6). This strong trend
toward hyperphosphorylation is consistent with the descriptions
of AD where the presence of NFTs and Tau aggregation is a diag-
nostic criterion and is closely related to the pathogenesis of this
dementia.
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FIGURE 3 | Variation in the levels of Tau and pTau after KOis of CDK5, GSK3β, PP2A, and PP1. K2 was modified, which decreased this value by 100%. The
inset in the figure indicates pTau variation compared with the basal condition.
FIGURE 4 | Variation in the levels of Tau and pTau in response to variations in calcium levels. Levels were increased 2-fold (0.2μM), 10-fold (1μM), and
100-fold (10μM). The inset in the graph shows the relative increase of pTau compared with the basal condition.
The SIS of CDK5 and GSK3β were assessed under the same
conditions, simulating a pathological state. The SIS of CDK5
and GSK3β separately influenced pTau levels similarly, although
CDK5 had a greater effect by decreasing pTau by 11.6%. In
addition, the simultaneous silencing of both kinases produced
a 28% decrease, reversing the effect caused by the pathological
conditions (Figure 6); this suggests a synergic activity between
depletion of the two kinases in decreasing pTau and emphasizes
the importance of intervening in the regulation of both proteins
in a disease process such as AD.
CONCLUSIONS
This review shows the dynamic complexity of a cellular sys-
tem that is in constant action. The scientific literature provides
largely isolated experimental data combined with theoretical data
capable of providing a specific cellular context. SB integrates
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FIGURE 5 | Variation in the levels of Tau and pTau in response to the SIS of CDK5 and GSK3β in conditions simulating excitotoxicity with a 100-fold
increase in calcium. CDK5 and GSK3β were silenced by 75%. The inset in the graph indicates the decrease in pTau in response to increased calcium.
FIGURE 6 | Changes in the levels of Tau and pTau in response
to SIS of CDK5 and GSK3β in conditions simulating AD
with increased calcium levels and a decrease in phosphatase
activity. CDK5 and GSK3β were silenced by 75%. The inset in
the graph indicates the decrease in pTau in response to
increased calcium.
experimental data and creates computational contexts limited
by existing data but that is dynamic, inclusive and is able to
create new questions to gain an understanding of biological phe-
nomena. In our previous experimental results show a chronic
disease model and the behavior of the molecular species after
the decrease of CDK5 (Piedrahita et al., 2010; Castro-Alvarez
et al., Submitted). Although more experiments are needed to
determine the causality of the results, the computational model
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FIGURE 7 | Hypothetic model of CDK5 knockdown action on reversion of
tauopathy in AD. The toxic events in AD induce imbalance between kinases
and phosphatases, where CDK5 overactivation produce hyperphospholylation
of Tau and neurodegeneration. Our in silico model can simulate it, when the
calcium increase induces more phosphorylation of Tau. However, CDK5
Silencing in vivo and in silico supported CDK5 as a node protein diminished
tauophaty through reversion of GSK3 β upregulation and preventing reduction
of phosphatases.
and the experimental results show the importance of GSK3β
and PP2A in conjunction with CDK5 in the process of Tau
hyperphosphorylation (Figure 7).
Our present computational model approximated the con-
ditions reported in the literature; thus, it was confirmed that
the deregulation of CDK5 induced by excitotoxicity is directly
involved in Tau hyperphosphorylation and that the inhibition of
this kinase in a murine model prevents Tau hyperphosphoryla-
tion and aggregation in association with the described pathway.
The work presented here indicates that PP2A is more important
than PP1 for Tau dephosphorylation and that its action regu-
lates phosphorylation events mediated by different kinases. In this
case, inhibition of CDK5 may increase phosphatase activity in the
context of a chronic disease, facilitating Tau dephosphorylation
and aiding in the disappearance of Tau aggregates. Together with
phosphatases, the synergistic role of CDK5 and GSK3β appears to
be essential for tauopathy, and decreased CDK5 inhibits GSK3β
function, which affects the disappearance of tauopathy.
Simulations using this model allowed the observation of the
behavior of Tau and p-Tau at different calcium concentrations;
however, it is important to describe in more detail the factors
involved in the proposed signaling cascade to build a model that
better approximates the chronic phenomenon of Tau hyperphos-
phorylation in AD. To this end, it is necessary to define in more
detail the PP2A and GSK3β signaling pathways to improve the
reproducibility of the model with other inputs. It is also essen-
tial to include new elements that may have a direct or indirect
action on Tau phosphorylation and that are not associated with
CDK5.
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